Circulating Proteins and Mortality in CKD: A Proteomics Study of the AASK and ARIC Cohorts

Nityasree Srialluri1,2, Aditya Surapaneni3,4, Pascal Schlosser3

  • 1Department of Medicine, Johns Hopkins University, Baltimore, Maryland.

Kidney Medicine
|September 15, 2023
PubMed

Insights

Proteomics identified 7 circulating proteins associated with mortality in chronic kidney disease (CKD) patients. Three proteins, including beta-2 microglobulin, were validated in a separate cohort, offering insights into CKD mortality risk.

Area of Science:

  • Nephrology
  • Proteomics
  • Epidemiology

Background:

  • Patients with chronic kidney disease (CKD) face an elevated risk of mortality.
  • Understanding the pathophysiological underpinnings of this mortality risk is crucial for improving patient outcomes.
  • Proteomic analysis offers a potential avenue to identify novel biomarkers associated with mortality in CKD.

Purpose of the Study:

  • To investigate the associations between circulating proteome and all-cause mortality in patients with CKD.
  • To identify specific proteins that can serve as predictors of mortality in CKD.
  • To validate these findings in an independent cohort.

Main Methods:

  • An observational cohort study was conducted using data from the African American Study of Kidney Disease and Hypertension (AASK) and the Atherosclerosis Risk in Communities (ARIC) study.
  • A large-scale proteomic analysis evaluated 6,790 circulating proteins for their association with all-cause mortality in the AASK cohort.
  • Significant proteins were validated in the ARIC cohort.

Main Results:

  • In the AASK cohort, 7 distinct proteins were significantly associated with all-cause mortality after multivariable adjustment.
  • In the ARIC cohort, 3 of these proteins—beta-2 microglobulin, spondin-1, and N-terminal pro-brain natriuretic peptide—were significantly associated with death.
  • These findings were robust across two distinct CKD cohorts.

Conclusions:

  • Large-scale proteomic analysis can identify circulating proteins reproducibly associated with mortality in CKD patients.
  • Specific proteins like beta-2 microglobulin may serve as valuable biomarkers for mortality risk in CKD.
  • Further research is warranted to explore the clinical utility of these identified biomarkers.
Abstract

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
34
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
41
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
29
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage kidney disease (ESKD). At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate...
33
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
200
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
118